Abstract  Description  Claims  Drawing  Search report  Cited references 

US62102966   [0001] 
US4946778A   [0036] 
US4816567A   [0036]  [0037]  [0037] 
US5545807A   [0036] 
US5545806A   [0036] 
US5569825A   [0036] 
US5625126A   [0036] 
US5633425A   [0036] 
US5661016A   [0036] 
WO9308829A   [0036]  [0100] 
US4676980A   [0036] 
WO9100360A   [0036] 
WO92200373A   [0036] 
EP03089A   [0036] 
US5530101A   [0037] 
US5859205A   [0037] 
US5585089A   [0037] 
US5693761A   [0037] 
US5693762A   [0037] 
US5777085A   [0037] 
US6180370B   [0037] 
US6210671B   [0037] 
US6329511B   [0037] 
WO8702671A   [0037] 
EP0173494A   [0037] 
WO20140051645A1   [0071] 
WO20140080177A   [0071] 
WO6277375A   [0092]  [0094] 
US4911920A   [0133] 
US5403841A   [0133] 
US5212162A   [0133] 
US4861760A   [0133] 

Tumor immunotherapy: preclinical and clinical activity of anti-CTLA-4 antibodies   [0002] 
Phase I/II study of ipilimumab for patients with metastatic melanoma   [0002] 
Nivolumab plus Ipilimumab in Advanced Melanoma   [0002] 
Proteins   [0018] 
Adv. Appl. Math.   [0023] 
J. Mol. Biol.   [0023] 
Proc. Nat'l. Acad. Sci. USA   [0023] 
Current Protocols in Molecular Biology   [0023] 
Nuc. Acids Res.   [0024] 
J. Mol. Biol.   [0024] 
Proc. Natl. Acad. Sci. USA   [0024] 
Proc. Natl. Acad. Sci. USA   [0025] 
Fundamental Immunology   [0034] 
Nature   [0034]  [0036] 
Nature   [0036] 
Immunology Today   [0036] 
Monoclonal Antibodies and Cancer Therapy   [0036] 
Current Protocols in Immunology   [0036] 
Antibodies, A Laboratory Manual   [0036] 
Monoclonal Antibodies: Principles and Practice   [0036] 
Immunology   [0036] 
Bio/Technology   [0036] 
Nature   [0036] 
Nature   [0036] 
Nature Biotechnology   [0036] 
Nature Biotechnology   [0036] 
Intern. Rev. Immunol.   [0036] 
Biotechnology   [0036] 
EMBO J.   [0036]  [0100] 
Methods in Enzymology   [0036]  [0100] 
Nature   [0037] 
Science   [0037] 
Nature   [0037] 
PNAS USA   [0037] 
Nature   [0037] 
Nature   [0037] 
Adv. Immunol.   [0037] 
Science   [0037] 
Curr. Op. Struct. Biol.   [0037] 
Molec. Immun.   [0037] 
Molec. Immun.   [0037] 
Monoclonal Antibodies For Immunotargeting Of Drugs In Cancer Therapy   [0039] 
Antibodies For Drug Delivery   [0039] 
Antibody Carriers Of Cytotoxic Agents In Cancer Therapy: A Review   [0039] 
The Preparation And Cytotoxic Properties Of Antibody-Toxin Conjugates   [0039] 
Using Antibodies, A Laboratory Manual   [0040] 
ADVANCED ORGANIC CHEMISTRY   [0083] 
BIOCONJUGATE TECHNIQUES   [0083] 
MODIFICATION OF PROTEINS   [0083] 
Cancer Immunity   [0092] 
Forntiers in Immunology   [0092] 
Pharmaceutical Dosage Forms   [0131] 
The Art, Science and Technology of Pharmaceutical Compounding   [0131] 
Dosage Calculations   [0131] 
Remington: The Science and Practice of Pharmacy   [0131] 
J. Biomater Sci. Polym. Ed.   [0133] 
Pharm. Res.   [0133] 
J. Pharm. Pharmacol.   [0133] 
J. Microencapsul.   [0133] 
Curr. Opin. Biotechnol.   [0133] 
Am. J. Hosp. Pharm.   [0133] 
Urine markers in monitoring for prostate cancer   [0142] 
Matrix metalloproteinases in cancer: their value as diagnostic and prognostic markers and therapeutic targets   [0142] 
Pituitary expression of CTLA-4 mediates hypophysitis secondary to administration of CTLA-4 blocking antibody   [0146] 
Exosite interactions contribute to tension-induced cleavage of von Willebrand factor by the antithrombotic ADAMTS13 metalloprotease   [0147] 
Label-free measurement of histone lysine methyltransferases activity by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry   [0147] 
Molecular insights into substrate specificity of prostate specific antigen through structural modeling   [0147] 
Engineering a prostate-specific membrane antigen-activated tumor endothelial cell prodrug for cancer therapy   [0147] 
Legumain protease-activated TAT-liposome cargo for targeting tumours and their microenvironment   [0147] 
Optimal subsite occupancy and design of a selective inhibitor of urokinase.   [0147] 
Proteomic identification of protease cleavage sites characterizes prime and non-prime specificity of cysteine cathepsins B, L, and S.   [0147] 
Targeting carcinoma-associated fibroblasts within the tumor stroma with a fibroblast activation protein-activated prodrug   [0147] 
Rationale behind targeting fibroblast activation protein-expressing carcinoma-associated fibroblasts as a novel chemotherapeutic strategy   [0147]